Last reviewed · How we verify

Esraa Salah Mohamed Abdallah Eladl — Portfolio Competitive Intelligence Brief

Esraa Salah Mohamed Abdallah Eladl pipeline: 1 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Salin Salin marketed Other

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  2. Bayer · 1 shared drug class
  3. Belén Retamal-Valdes · 1 shared drug class
  4. Benova (Tianjin) Innovative medicine Research Co., Ltd. · 1 shared drug class
  5. Incheon St.Mary's Hospital · 1 shared drug class
  6. International Maternal Pediatric Adolescent AIDS Clinical Trials Group · 1 shared drug class
  7. KEMRI-Wellcome Trust Collaborative Research Program · 1 shared drug class
  8. National Taiwan University Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Esraa Salah Mohamed Abdallah Eladl:

Cite this brief

Drug Landscape (2026). Esraa Salah Mohamed Abdallah Eladl — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/esraa-salah-mohamed-abdallah-eladl. Accessed 2026-05-16.

Related